Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ACAD

ACAD - ACADIA Pharmaceuticals Inc Stock Price, Fair Value and News

15.10USD-0.27 (-1.76%)Market Closed

Market Summary

ACAD
USD15.10-0.27
Market Closed
-1.76%

ACAD Alerts

  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

ACAD Stock Price

View Fullscreen

ACAD RSI Chart

ACAD Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-1.5K

Price/Sales (Trailing)

3.12

EV/EBITDA

144.3

Price/Free Cashflow

39.89

ACAD Price/Sales (Trailing)

ACAD Profitability

EBT Margin

1.83%

Return on Equity

-0.37%

Return on Assets

-0.2%

Free Cashflow Yield

2.51%

ACAD Fundamentals

ACAD Revenue

Revenue (TTM)

813.8M

Rev. Growth (Yr)

73.75%

Rev. Growth (Qtr)

-10.91%

ACAD Earnings

Earnings (TTM)

-1.7M

Earnings Growth (Yr)

138.48%

Earnings Growth (Qtr)

-63.85%

Breaking Down ACAD Revenue

Last 7 days

0.3%

Last 30 days

1.3%

Last 90 days

-17.9%

Trailing 12 Months

-38.6%

How does ACAD drawdown profile look like?

ACAD Financial Health

Current Ratio

2.04

ACAD Investor Care

Shares Dilution (1Y)

1.60%

Diluted EPS (TTM)

-0.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024813.8M000
2023520.2M550.9M631.9M726.4M
2022493.1M512.4M511.5M517.2M
2021458.2M463.4M474.4M484.1M
2020366.2M393.1M419.1M441.8M
2019237.9M264.0M300.3M339.1M
2018158.5M185.1M207.8M223.8M
201740.2M63.0M93.3M124.9M
20164.4M8.7M13.0M17.3M
201500129.0K118.0K
2014758.0K335.0K110.0K120.0K
20134.9M4.7M1.5M1.1M
20122.1M2.2M5.1M4.9M
201132.1M22.1M12.1M2.1M
2010018.3M30.2M42.1M
20090006.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of ACADIA Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
schneyer mark c.
sold
-14,420
14.79
-975
evp, chief financial officer
Jun 08, 2024
schneyer mark c.
acquired
-
-
1,893
evp, chief financial officer
May 29, 2024
garofalo elizabeth a.
acquired
-
-
6,652
-
May 29, 2024
harrigan edmund
acquired
-
-
6,652
-
May 29, 2024
ndu adora
acquired
-
-
6,652
-
May 29, 2024
baker bros. advisors lp
acquired
-
-
37,548
-
May 29, 2024
daly james m
acquired
-
-
6,652
-
May 29, 2024
brege laura
acquired
-
-
6,652
-
May 29, 2024
soland daniel b
acquired
-
-
6,652
-
May 02, 2024
kihara james
sold
-22,462
16.94
-1,326
principal accounting officer

1–10 of 50

Which funds bought or sold ACAD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
445
1,317
2,006
-%
Jun 04, 2024
DekaBank Deutsche Girozentrale
added
2.89
-1,180,000
1,745,000
-%
May 28, 2024
Verity Asset Management, Inc.
new
-
215,741
215,741
0.12%
May 24, 2024
Cetera Investment Advisers
new
-
213,726
213,726
-%
May 22, 2024
Livelsberger Financial Advisory
unchanged
-
-1,201
1,147
0.01%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.73
-8,718
585,282
0.07%
May 20, 2024
Virtu Financial LLC
new
-
285,000
285,000
0.02%
May 16, 2024
COMERICA BANK
reduced
-97.77
-1,306,860
17,458
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-15.74
-7,020,820
6,953,370
-%
May 16, 2024
Arete Wealth Advisors, LLC
new
-
295,840
295,840
0.03%

1–10 of 40

Are Funds Buying or Selling ACAD?

Are funds buying ACAD calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACAD
No. of Funds

Unveiling ACADIA Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
rtw investments, lp
6.9%
11,253,551
SC 13G
Feb 13, 2024
vanguard group inc
8.16%
13,396,009
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 26, 2024
blackrock inc.
6.9%
11,409,218
SC 13G/A
May 24, 2023
baker bros. advisors lp
26.5%
43,084,280
SC 13D/A
Feb 14, 2023
price t rowe associates inc /md/
2.6%
4,279,254
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.20%
13,279,775
SC 13G/A
Feb 01, 2023
blackrock inc.
6.3%
10,258,738
SC 13G/A
Jan 17, 2023
baker bros. advisors lp
26.0%
42,163,470
SC 13D/A

Recent SEC filings of ACADIA Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 29, 2024
S-8 POS
Employee Benefits Plan
May 29, 2024
S-8 POS
Employee Benefits Plan

Peers (Alternatives to ACADIA Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
17.55% 15.42%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.1B
2.0B
6.10% -19.49%
-60.58
10.04
75.20% 68.82%
16.1B
2.5B
5.03% -10.77%
78.14
6.5
13.74% 186.89%
13.5B
3.8B
4.06% -3.24%
18.05
3.57
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.63% 71.22%
-9.82
48.09
54.84% -28.31%
5.2B
524.1M
-1.19% -54.45%
-12.36
9.84
394.93% 39.61%
3.4B
251.0M
-5.41% -4.45%
-11.47
13.54
73.58% -86.73%
3.2B
240.7M
16.82% -26.89%
-6.77
12.77
-1.03% -213.92%
2.5B
813.8M
1.25% -38.59%
-1.5K
3.12
56.43% 98.83%
2.1B
996.6M
20.98% 97.26%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-4.75% 32.39%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
19.55% 492.49%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-16.55% 51.92%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
40.11% 239.32%
-0.95
7.61
-13.45% 69.54%

ACADIA Pharmaceuticals Inc News

Latest updates
MarketBeat115 minutes ago
StockNews.com02 May 202407:00 am

ACADIA Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-10.9%205,831,000231,041,000211,699,000165,235,000118,462,000136,490,000130,714,000134,563,000115,468,000130,758,000131,612,000115,221,000106,554,000121,007,000120,577,000110,103,00090,068,00098,326,00094,586,00083,205,00062,959,000
Costs and Expenses-2.8%190,621,000196,097,000269,475,000162,198,000172,046,000182,553,000161,580,000168,214,000228,484,000175,415,000146,913,000158,930,000173,326,000188,169,000206,476,000154,113,000179,583,000154,725,000140,007,000140,296,000150,593,000
  S&GA Expenses-3.1%107,991,000111,465,50097,890,00095,968,000101,235,000104,402,00078,108,00089,901,00096,679,000105,912,00081,666,00096,789,000111,661,000120,752,00081,592,00084,344,000101,973,00091,871,00072,696,00067,981,00093,090,000
  R&D Expenses-10.6%59,679,00066,741,000156,963,00058,771,00069,144,00075,738,00081,336,00075,646,000128,855,00066,942,00058,565,00056,935,00056,973,00062,116,000120,083,00064,295,00072,636,00057,520,00062,622,00067,320,00052,923,000
EBITDA Margin129.2%0.02-0.07-0.21-0.19-0.28-0.41-0.42-0.39-0.43-0.34-0.40-0.56---------
Income Taxes172.4%4,400,000-6,081,00013,033,0005,229,000-1,900,000835,000768,000443,000485,000189,000-332,000473,00021,000417,000-199,000393,000-400,000-264,000365,000375,000
Earnings Before Taxes-47.1%21,000,00039,662,000-52,100,0006,343,000-44,900,000-40,851,000-26,415,000-33,600,000-112,571,000-42,905,000-14,789,000-43,398,000-66,427,000-66,343,000-84,859,000-41,748,000-88,023,000-52,636,000-42,242,000-54,576,000-84,929,000
EBT Margin126.1%0.02-0.07-0.21-0.19-0.28-0.41-0.42-0.40-0.43-0.35-0.40-0.56---------
Net Income-63.9%16,555,00045,797,000-65,176,0001,114,000-43,021,000-41,725,000-27,183,000-34,011,000-113,056,000-43,094,000-14,457,000-43,871,000-66,448,000-66,760,000-84,660,000-42,141,000-88,023,000-53,036,000-41,978,000-54,941,000-85,304,000
Net Income Margin97.5%0.00-0.08-0.24-0.20-0.28-0.42-0.42-0.40-0.43-0.35-0.40-0.56---------
Free Cashflow-65.9%29,079,00085,389,000-58,955,0008,201,000-17,933,000-23,854,000-727,000-13,125,000-76,329,000-23,121,000-17,064,000-25,372,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets14.2%855749633643655588602613624700718724755783796760747783766461501
  Current Assets9.6%675616499493503508522533542618641646674718730736724760742437476
    Cash Equivalents8.5%20518998.0010829111515514020514795.0026730432645231017319038574.0098.00
  Inventory64.8%67.0040.00--------14.0011.0010.0010.008.006.006.006.005.004.005.00
  Net PPE-5.2%4.005.005.005.006.006.007.007.008.008.009.009.0010.009.008.007.005.003.003.003.004.00
Liabilities23.3%39131727024728118717717817915915116017415614197.0010984.0076.0072.0083.00
  Current Liabilities30.0%33125421018822412611711812096.0088.0095.0010910692.0086.0010075.0068.0064.0075.00
Shareholder's Equity7.5%464432362396374400426435445541567565582627655663638699689389418
  Retained Earnings0.7%-2,414-2,430-2,476-2,411-2,412-2,369-2,327-2,300-2,266-2,153-2,110-2,096-2,052-1,985-1,918-1,834-1,792-1,704-1,651-1,609-1,554
  Additional Paid-In Capital0.6%2,8792,8632,8392,8082,7872,7712,7552,7362,7122,6952,6772,6612,6342,6132,5732,4962,4292,4032,3401,9971,972
Shares Outstanding0.2%165165164163162162162162161161161161---------
Float----2,900---1,700---2,500---4,600---2,200-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-65.9%29,07985,389-58,9558,201-17,933-23,854-727-13,125-76,329-23,120-17,064-25,327-60,149-27,488-22,793-36,883-49,002-29,707-18,851-38,397-64,175
  Share Based Compensation-18.2%14,75018,02318,53915,15414,70514,41418,31220,51214,96312,88015,54622,00513,18421,19521,37219,50722,34819,85022,02320,42219,883
Cashflow From Investing-3945.8%-14,039-34734,110-194,283192,518-17,74815,441-55,797131,34571,549-156,321-17,20730,877-116,958152,994126,86529,608-209,1449,92310,62722,758
Cashflow From Financing-80.8%1,0435,43412,7515,4781,4661,6142873,8312,4674,3651,0665,0057,72618,12611,71547,4013,75443,058319,9674,6464,176
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ACAD Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues  
Type of Revenue [Extensible List]us-gaap:ProductMemberus-gaap:ProductMember
Total revenues$ 205,831$ 118,462
Operating expenses  
Type of Cost, Good or Service [Extensible List]us-gaap:ProductMemberus-gaap:ProductMember
Cost of product sales$ 22,951$ 1,667
Research and development59,67969,144
Selling, general and administrative107,991101,235
Total operating expenses190,621172,046
Income (loss) from operations15,210(53,584)
Interest income, net5,5063,800
Other income2864,845
Income (loss) before income taxes21,002(44,939)
Income tax expense (benefit)4,447(1,918)
Net Income (Loss)$ 16,555$ (43,021)
Earnings (net loss) per share, basic$ 0.1$ (0.27)
Earnings (net loss) per share, diluted$ 0.1$ (0.27)
Weighted average common shares outstanding, basic164,798162,263
Weighted average common shares outstanding, diluted166,623162,263

ACAD Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets  
Cash and cash equivalents$ 204,745$ 188,657
Investment securities, available-for-sale265,775250,208
Accounts receivable, net94,70198,267
Interest and other receivables5,3784,083
Inventory61,93635,819
Prepaid expenses42,76139,091
Total current assets675,296616,125
Property and equipment, net4,3704,612
Operating lease right-of-use assets54,28051,855
Intangible assets, net110,20465,490
Restricted cash5,7705,770
Long-term inventory4,7074,628
Other assets476476
Total assets855,103748,956
Liabilities and stockholders’ equity  
Accounts payable19,33217,543
Accrued liabilities311,265236,711
Total current liabilities330,597254,254
Operating lease liabilities49,18947,800
Other long-term liabilities11,27315,147
Total liabilities391,059317,201
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 5,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 andDecember 31, 202300
Common stock, $0.0001 par value; 225,000,000 shares authorized at March 31, 2024 and December 31, 2023; 164,959,736 shares and 164,650,219 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively1616
Additional paid-in capital2,878,5392,862,552
Accumulated deficit(2,414,282)(2,430,837)
Accumulated other comprehensive loss(229)24
Total stockholders’ equity464,044431,755
Total liabilities and stockholders’ equity$ 855,103$ 748,956
ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
 CEO
 WEBSITEhttps://acadia.com
 INDUSTRYBiotechnology
 EMPLOYEES540

ACADIA Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for ACADIA Pharmaceuticals Inc? What does ACAD stand for in stocks?

ACAD is the stock ticker symbol of ACADIA Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ACADIA Pharmaceuticals Inc (ACAD)?

As of Wed Jun 12 2024, market cap of ACADIA Pharmaceuticals Inc is 2.54 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACAD stock?

You can check ACAD's fair value in chart for subscribers.

What is the fair value of ACAD stock?

You can check ACAD's fair value in chart for subscribers. The fair value of ACADIA Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ACADIA Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACAD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ACADIA Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ACAD is over valued or under valued. Whether ACADIA Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ACADIA Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACAD.

What is ACADIA Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, ACAD's PE ratio (Price to Earnings) is -1485.06 and Price to Sales (PS) ratio is 3.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACAD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ACADIA Pharmaceuticals Inc's stock?

In the past 10 years, ACADIA Pharmaceuticals Inc has provided -0.04 (multiply by 100 for percentage) rate of return.